An observational study in Asthma and COPD, sponsored by Orion Corporation, Orion Pharma. Terminated at 1 site in Norway. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-09-23.
Sponsored by Orion Corporation, Orion Pharma · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Asthma by Orion Corporation, Orion Pharma — none open to participants now, none under way, none of them phase 3. Asthma · Orion Corporation, Orion Pharma.
Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, this one is the only one that started in 2020, is one of 2 observational ones, and was the 19th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →None of the 21 studies in Asthma by Orion Corporation, Orion Pharma is open now. The open studies under Asthma, anywhere →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 1 · Phase 3 1 · Phase 4 2
First in 2009; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 72 across the 19 interventional studies, 130 across the 2 observational. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Asthma by Orion Corporation, Orion Pharma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.
In July 2018 Norwegian authorities decided to allow switch at pharmacy for dry powder inhalers (DPIs) containing budesonide-formoterol. Pharmacists are instructed to switch patients to the inhaler with the lowest price. The pharmacist will train the patient on how to use the new inhaler. All patients whose eligible inhaler switch occurred between 1st July 2018 and 1st March 2019 will be eligible for the study.
Patients with asthma and/or COPD treated with budesonide-formoterol DPI
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dry powder inhaler
Disease control
The number of asthma and/or COPD exacerbations during the 12 months pre-switch and the 12 months post-switch.
Time frame: 24 months
Budesonide-formoterol dose
The change in the treatment dose of budesonide-formoterol at the time of the eligible switch and at the end of the post-switch period (e.g. 12 months post-switch).
Time frame: 24 months
Training at pharmacy
The correlation between inhaler training given at pharmacy and exacerbations.
Time frame: 24 months
Healthcare utilisation
The number of asthma and/or COPD related hospitalisations, emergency room visits and visits to physicians 12 months pre-switch and 12 months post-switch.
Time frame: 24 months
Inhaler switch
The number of re-switches after the first 'eligible' switch and the reasons for that switch.
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2020 to primary completion in Sep 2021, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orion Corporation, Orion Pharma →